Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targeted cancer therapies, but its wider use has been limited by production capacity. This partnership will leverage Telix's radiopharmaceutical network to establish the first US production facility in Pennsylvania, with plans for further expansion. The collaboration aims to enhance access to innovative cancer treatments and strengthen the supply chain for this critical isotope.
Ekalia's collaboration with Telix Pharmaceuticals to boost astatine-211 production in the US is notable amid a health sector where 79 of 150 US stocks traded on Pluang rose today. For readers following this sector, here is Pluang's market snapshot as of Oct 19, 2026 13:11 WIB: GeneDx Holdings Corp (WGS) traded at USD 63.80 with a 7.01% decrease, Travere Therapeutics Inc. (TVTX) at USD 49.60 down 6.89%, and Adaptive Biotechnologies Corp (ADPT) at USD 24.02 down 6.25%.
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
Primary Health Properties PLC has partnered with Singapore's GIC to create a £700 million joint venture comprising 27 private hospitals. The deal, expected to complete in November, will generate about £500 million in net proceeds for Primary Health P...
